COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer (HRPC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00525408
Recruitment Status : Terminated (Interim Analysis report indicates trial futility)
First Posted : September 5, 2007
Last Update Posted : March 12, 2012
Information provided by (Responsible Party):
Cadila Pharnmaceuticals

No Study Results Posted on for this Study
Recruitment Status : Terminated
Estimated Primary Completion Date : January 2013
Estimated Study Completion Date : January 2013